Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome

Irritable bowel syndrome (IBS) is a chronic functional disorder and its development may be linked, directly and indirectly, to intestinal dysbiosis. Here we investigated the interactions between IBS symptoms and the gut microbiome, including the relation to rifaximin (1200 mg daily; 11.2 g per a tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeber-Lubecka, Natalia, Kulecka, Maria, Ambrozkiewicz, Filip, Paziewska, Agnieszka, Goryca, Krzysztof, Karczmarski, Jakub, Rubel, Tymon, Wojtowicz, Wojciech, Mlynarz, Piotr, Marczak, Lukasz, Tomecki, Roman, Mikula, Michal, Ostrowski, Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Research Paper/Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046165/
https://www.ncbi.nlm.nih.gov/pubmed/27662586
http://dx.doi.org/10.1080/19490976.2016.1215805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046165/
https://www.ncbi.nlm.nih.gov/pubmed/27662586
http://dx.doi.org/10.1080/19490976.2016.1215805

Ejemplares similares